Several years ago our co-founders, George Goldsmith and Ekaterina Malievskaia, experienced the painful effects of depression within their own family. They discovered first-hand how hard it can be to find adequate mental health care for a loved one, and met many other patients and families who felt similarly helpless.

Motivated to find a new approach to mental health care, together with third co-founder Lars Christian Wilde, they started COMPASS with a commitment to putting patients at the heart of the company’s purpose.

At COMPASS, our vision is for a world of mental wellbeing. Every one of us is committed to discovering and developing new therapies that will help patients and their families, and ease the burden on our overstretched healthcare systems. For too many people, mental health care today isn’t good enough. We are determined to change that.

Our first major initiative is developing psilocybin therapy through late-stage clinical trials in Europe and North America for people with treatment-resistant depression. Read more about our science.

Recent News

Get the Compass
Investor’s Kit now.

Compounds

Market Cap

NASDAQ: CMPS

Focus